NCT06457217 MRSI Evaluation for Minor Stroke With Large Vessel Occlusion
| NCT ID | NCT06457217 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai 6th People's Hospital |
| Condition | Acute Ischemic Stroke |
| Study Type | OBSERVATIONAL |
| Enrollment | 75 participants |
| Start Date | 2024-08-15 |
| Primary Completion | 2027-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 75 participants in total. It began in 2024-08-15 with a primary completion date of 2027-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to understand acute anterior circulation large artery occluded minor stroke (LVO-MIS) evolution using magnetic resonance spectroscopic imaging evaluation. The main questions it aims to answer are: 1. Neurometabolic predictors of early neurological deterioration and functional outcome; 2. Temporal and spatial dynamic changes of the neurometabolites from the acute stage (within 24 hours), through the subacute stage (5-7 days), to the chronic stage (90 days); 3. Temporal and spatial dynamic changes of the neurotransmitters GABA, glutamate, and glutamine from the acute stage to the chronic stage; 4. Brain regions exhibiting changes in whole-brain metabolic network connectivity.
Eligibility Criteria
Inclusion Criteria: 1. Adult (age ≥ 18 years) patients presenting with symptoms consistent with acute ischemic stroke due to occlusion of the intracranial internal carotid artery and/or M1 or M2 segment of the middle cerebral artery; 2. Patients with mild symptoms at admission (National Institutes of Health Stroke Scale (NIHSS)\<6); 3. Baseline multimodal-CT imaging, including NCCT, CTA and CTP, performed at the trial-site hospital; 4. Time from symptom onset or last known normal to enrollment is less than 24 hours; 5. Patient or legal representative willing to comply with protocol requirements and data collection procedures, understand and sign informed consent. Exclusion Criteria: 1. A pre-incident mRS ≥ 1 point before onset; 2. Previous clear history of cerebral infarction, cerebral hemorrhage, brain tumor and other diseases that affect cerebral metabolism; 3. Intolerance or non-cooperation with magnetic resonance examination; 4. Severe cardiac, hepatic, renal impairment or other systemic serious advanced diseases; 5. Pregnancy or lactation; 6. Life expectancy is less than 3 months; 7. Other conditions that, in the opinion of the investigator, are not suitable for participation in this study or may pose a significant risk to the patient (such as inability to understand and/or comply with study procedures and/or follow-up due to psychiatric disorders, cognitive or emotional disorders).
Contact & Investigator
Li Cao, phD
PRINCIPAL INVESTIGATOR
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Frequently Asked Questions
Who can join the NCT06457217 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Acute Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06457217 currently recruiting?
Yes, NCT06457217 is actively recruiting participants. Contact the research team at caoli2000@yeah.net for enrollment information.
Where is the NCT06457217 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06457217 clinical trial?
NCT06457217 is sponsored by Shanghai 6th People's Hospital. The principal investigator is Li Cao, phD at Shanghai Jiao Tong University Affiliated Sixth People's Hospital. The trial plans to enroll 75 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.